Arbios Systems Chief Scientific Officer Presents at The Acute Liver Failure Workshop, Sponsored By The NIH
December 05 2006 - 10:39AM
PR Newswire (US)
Dr.Jacek Rozga Invited to Present Rationale for the SEPET(TM) Liver
Assist Device WALTHAM, Mass., Dec. 5 /PRNewswire-FirstCall/ --
Arbios Systems, Inc. (OTC:ABOS), a company developing proprietary
medical devices and cell-based therapies for the millions of
patients each year who experience or are at risk for
life-threatening episodes of liver failure, today announced that
Jacek Rozga, M.D., Ph.D., Founder and Chief Scientific Officer, has
been invited to present at The Acute Liver Failure Workshop, which
began yesterday and continues today at the Hyatt Regency Bethesda,
in Bethesda, MD. The meeting is sponsored by the Liver Disease
Research Branch of the Division of Digestive Diseases and Nutrition
of the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) of the National Institutes of Health (NIH), in
collaboration with the Food and Drug Administration (FDA) and other
federal agencies. Dr. Rozga's presentation, entitled, "Plasma
Filtration Therapy of Acute Liver Failure, takes place this
morning, December 5th at 10:50 a.m. Eastern Time. His presentation
focused on rationales for use of Arbios' SEPET(TM) Liver Assist
Device technology for removal from the blood of small and middle
molecular weight molecules, including inflammatory cytokines and
conventional toxins including those bound to albumin, which are
implicated in poor patient outcomes from acute liver failure. Dr.
Rozga will further address rationales for potential benefit of
SEPET(TM) plasma filtration therapy in the treatment of conditions
related to, and often arising as a result of, liver failure,
including multi-organ failure, systemic inflammatory response
syndrome, and severe sepsis. Dr. Rozga will also summarize the
previously announced favorable progress of Arbios' ongoing
feasibility clinical trial of the SEPET(TM) Liver Assist Device.
About The Acute Liver Failure Workshop To aim of the Acute Liver
Failure Meeting, which brings together some of the best scientific
minds in the medical community, is to assess current knowledge
about acute liver failure, including its causes, incidence, natural
history, management, and prevention. The meeting will also make
recommendations for directions for future research, both basic and
clinical. Topics will include: epidemiology; current causes and
secular trends in distribution of etiologies; natural history and
course; specific and nonspecific management; acetaminophen as a
cause of liver injury and intentional vs. unintentional
acetaminophen overdose; causes of acute liver injury in children
and the role of acetaminophen; autoimmunity as a cause of acute
liver failure; changes in frequency of viral hepatitis as a cause
of acute liver failure; liver transplantation, including living
donor liver transplantation; innovative therapies for acute liver
failure including hypothermia and role of bioartificial liver
support systems and albumin dialysis. The workshop will also focus
on needs for future research. About Arbios Systems Arbios Systems,
Inc. is developing proprietary medical devices and cell- based
therapies to enhance the survival of millions of patients each year
who experience, or are at risk for, life-threatening episodes of
liver failure. The Arbios product candidate portfolio includes the
SEPET(TM) Liver Assist Device, a novel blood purification therapy
that provides enhanced "liver dialysis," and the HepatAssist(TM)
Cell-Based Liver Support System, a bioartificial liver that
combines blood detoxification with liver cell therapy to replace
whole liver function in patients with the most severe forms of
liver failure. This press release contains forward-looking
statements that involve risks and uncertainties that could cause
actual events or results to differ materially from the events or
results described in the forward-looking statements, including
risks or uncertainties related to the goals and results of clinical
trials, compliance with regulatory requirements, labeling of the
Company's products, the need for subsequent substantial additional
financing to complete clinical development of its products, future
markets and demand for the Company's products, and Arbios' ability
to successfully market its products and technologies. These
statements represent the judgment of Arbios' management as of this
date and are subject to risks and uncertainties that could
materially affect the Company. Arbios cautions investors that there
can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such
forward-looking statements. Please refer to our Annual Report on
Form 10-KSB for the fiscal year ended December 31, 2005 for a
description of risks that may affect our results or business
conditions. The Company does not undertake any obligation to
publicly release the result of any revisions to such
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, except as required by law. SEPET(TM) and
HepatAssist(TM) are trademarks of Arbios Systems, Inc. DATASOURCE:
Arbios Systems, Inc. CONTACT: Walter C. Ogier, of Arbios Systems,
Inc., +1-781-839-7293, ; or Doug MacDougall, MacDougall Biomedical
Communications, +1-508-647-0209; Investors - Paula Schwartz,
+1-917-322-2216, Media - Pat Garrison, +1-917-322-2567, both of RX
Communications Group Web site: http://www.arbios.com/
Copyright